Tradestie Institutional Equity Comparison Engine

SGMO vs LAZR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SGMO Overall Edge

SGMO Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sangamo Therapeutics, Inc. Common Stock (SGMO) driven by superior Valuation, Growth & Margin, Options & Structure while LAZR counters with relative strength in Momentum & Technical. Fundamentally, SGMO trades at 0.4x Forward P/E with -175.5% operating margin (+88.4% YoY revenue) versus LAZR at N/M Forward P/E and -340.9% operating margin (+21.0% YoY). In options structure, SGMO sits in UNCLASSIFIED (71st %ile IV; Dealer Gamma Walls on Pro) against LAZR sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner SGMO
SGMO 0.4x vs LAZR N/M Fwd P/E
Growth & Margin Winner SGMO
Op Margin -175.5% vs -340.9% ยท YoY +88.4% vs +21.0%
Momentum & Technical Winner LAZR
1Y -76.0% vs +469.8% ยท 52W Pos 9% vs 53%
Options & Structure Winner SGMO
UNCLASSIFIED (71st %ile IV) vs BREAKDOWN (8th %ile IV)
SGMO NASDAQ
Sangamo Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.18
+31.56% 1D
Market Cap $55.9M
1M Return -40.82%
1Y Return -76.04%
Forward P/E 0.4x
Unified AI Score
52.0 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 65.0 Mom 60.0
LAZR NASDAQ
Luminar Technologies, Inc. Class A Common Stock
Motor Vehicle Parts & Accessories
$27.12
-7.28% 1D
Market Cap $14.7M
1M Return -25.51%
1Y Return +469.75%
Forward P/E N/M
Unified AI Score
46.3 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 58.0 Mom 70.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SGMO -76.04% LAZR +469.75% Spread: +94.98 pp (SGMO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SGMO TTM Op. Margin: -175.5% LAZR TTM Op. Margin: -340.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SGMO vs LAZR. Trailing 12-month operating profitability (SGMO -175.5% vs LAZR -340.9%) and valuation multiples (SGMO 0.4x vs LAZR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SGMO (6) vs LAZR (3)
Institutional Metric SGMO LAZR Criterion Row Winner
Market Capitalization Scale $55.9M $14.7M Larger Scale SGMO
Trailing P/E Ratio Valuation 0.4x N/M Lower Multiple SGMO
Forward P/E Ratio Valuation 0.4x N/M Lower Multiple SGMO
Revenue Growth (YoY) Growth +88.4% +21.0% Higher Growth SGMO
Operating Margin (TTM) Profitability -175.5% -340.9% Higher Margin SGMO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -2891.8% -2424.7% Higher ROE LAZR
52-Week Range Position Momentum 9% ($0โ€“$1) 53% ($0โ€“$51) Stronger Trend LAZR
Beta / 30D Volatility Risk Regime 1.49ฮฒ ยท 206% Vol 3.66ฮฒ ยท 99% Vol Lower Realized Risk LAZR
Unified Institutional Score Composite Signal 52.0 / 100 (HOLD) 46.3 / 100 (HOLD) Higher Composite SGMO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SGMO vs LAZR Buy Guide
SGMO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 71st %ile
IV Regime Elevated (60thโ€“80th %ile)
Live SGMO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LAZR BREAKDOWN
97d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live LAZR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SGMO nor LAZR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.